Optimizing and Personalizing Treatment in Generalized Myasthenia Gravis

The treatment landscape for generalized myasthenia gravis (gMG) has evolved considerably in recent years, with an expanding range of targeted therapies offering new opportunities to improve disease management. As treatment options become more diverse, clinicians are increasingly considering factors beyond efficacy alone, including speed of response, durability, long-term safety, and treatment burden. These advances are also reshaping therapeutic goals, placing greater emphasis on restoring patient function and improving quality of life rather than solely preventing exacerbations and myasthenic crises.

In this NeurologyLive^® Special Report, Ali Habib, MD, a neuromuscular specialist at UCI Health, provides insights into the phase 3 NIMBLE trial (NCT05070858), which evaluated the investigational small interfering RNA therapeutic cemdisiran in adults with gMG. Speaking with NeurologyLive during the 2026 AANEM Annual Meeting, held September 29 to October 2 in Orlando, Florida, Habib discussed the trial's efficacy and safety findings in the context of an increasingly diverse therapeutic landscape. The study evaluated cemdisiran administered subcutaneously every 12 weeks, offering a distinct dosing approach among emerging complement-targeted therapies.

In this episode, Habib discusses how the growing number of treatment options is challenging clinicians to pursue more ambitious outcomes for patients with gMG. He examines the importance of faster treatment responses, sustained efficacy, and dosing convenience when individualizing care, while also highlighting the potential advantages of cemdisiran's investigational dosing schedule. The conversation underscores how therapeutic advances are shifting clinical priorities toward greater functional independence and long-term quality of life.

Transcript edited for clarity.

Ali Habib, MD: as you mentioned, we have what I've been calling an embarrassment of riches when it comes to therapeutic options, and that's fantastic because what that has done is challenge us to raise the bar in terms of outcomes for patients.

The conversation is no longer about just preventing myasthenic crises or disease exacerbations, but really returning patients to a higher level of quality of life, for them to be able to engage in activities that are meaningful to them and continue to be productive in their careers and in their lives.

These therapeutic options have really helped us advance those goals and achieve those goals. One of the things that I feel has been the biggest change over time in the field is that we've had effective therapies, but they've taken time to take effect and show that benefit, and long-term safety has been a concern.

So, the growing armamentarium has basically allowed us to have a faster onset of action, potentially greater depth of response, and durability of response over time.

What cemdisiran brings to the table is those factors, along with a very favorable dosing schedule. Whereas a lot of our newer therapies require periodic dosing, the dosing interval for cemdisiran, with once-every-12-week dosing, which really translates to about 4 treatments in a year, is phenomenal.

We haven't hit that mark in terms of dosing frequency with most of our downstream therapies. Inebilizumab is there, and that is once-every-6-month dosing, but it's an upstream mechanism that's being targeted with that.